nucleic acid semi-quantitation and molecular macrolide resistance detection via automated assays: gender and specimen source considerations.

Unlabelled: A laboratory-developed test (LDT) using analyte-specific reagents has been optimized on a commercial platform to detect macrolide resistance-associated mutations (MRM) in 23S rRNA from from primary clinical specimens. In this study, MRM-LDT was applied to a multi-specimen source study set. One thousand four hundred ninety-five primary specimens testing positive for by commercial transcription-mediated amplification (TMA) were initially titered by the TMA assay using serial 10-fold dilutions to semi-quantitate target nucleic acid burden. Primary specimens were then processed for MRM detection using the MRM-LDT. Findings were stratified by gender and specimen source. The mean log target nucleic acid titer of a TMA-positive specimen was 3.51 (median 3; range 0-10). Male specimens ( = 1145) demonstrated a mean log TMA titer of 3.67; that value observed in 350 female specimens was 2.98 ( < 0.0001). The MRM-LDT detection rate (88.7%) from specimens with log TMA titers ≥ 4 was increased over specimens with log titers ≤ 1 (4.5%; < 0.0002). In females, MRM-LDT was positive from 51.3% of vaginal swab and 34.7% of urine specimens ( = 0.01). In males, MRM-LDT was positive from 65.0% of rectal swab and 55.7% of urine specimens ( = 0.002). Differences were also observed in log TMA titers as a function of specimen source. macrolide resistance rates among multiple specimen sources, as determined by MRM-LDT, are high in the United States and can be consistent with target nucleic acid burden within the primary specimen. Caveats experienced within subgroupings support MRM reflex testing on primary -positive specimens.

Importance: First-line macrolide treatment failure is of increasing concern with in multiple settings. Recent sexually-transmitted infection treatment guidelines from the United States Centers for Disease Control and Prevention have predicated therapeutic approaches on the availability of a macrolide resistance/susceptibility result from a primary clinical specimen. In this report, we investigate potential correlation between macrolide resistance mutation detection rates (identified by a molecular amplified laboratory-developed test) and transcription-mediated amplification-based rRNA target semi-quantitation. Data reveal that rRNA semi-quantitation and laboratory-developed test detection rate differences exist as a function of gender and specimen source. These data can guide providers in proper specimen selection not only for the laboratory diagnosis of but also macrolide resistance mutation determination from primary clinical specimens.